Skip to content

Fertility and sexuality following cancer

Fex-Can – interventions to alleviate impact of cancer on fertility and sexuality among adolescents and young adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN36621459
Enrollment
150
Registered
2016-01-25
Start date
2017-02-01
Completion date
Unknown
Last updated
2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescents and young adults diagnosed with selected cancers (lymphoma, testicular cancer, ovarian cancer, breast cancer, cervix cancer and CNS tumors). Cancer

Interventions

Individuals will be identified through national cancer registers, approached by postal mail one year post-diagnosis and asked to complete standardized questionnaires. Those rating high levels of ferti

Sponsors

Karolinska Institutet
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with lymphoma, testicular cancer, ovarian cancer, breast cancer, cervix cancer and tumors of the central nervous system 2. Twelve months post-diagnosis 3. Aged 15 to 39 at diagnosis 4. Rating fertility-related distress or sexual dysfunction

Exclusion criteria

Exclusion criteria: Patients who do not understand and speak the Swedish language

Design outcomes

Primary

MeasureTime frame
1. Fertility-related distress, measured with the Reproduction Concerns After Cancer (RCAC) scale 2. Sexual function, measured with the PROMIS Sexual Function and Satisfaction Measures (global satisfaction with sex life, interest in sexual activity, lubrication, vaginal discomfort, erectile function, orgasm) and selected items developed for use among cancer populations The effect of the intervention will be evaluted 12 weeks (T2) and 24 weeks (T3) after randomization (short-term evaluation), and 3 years (T4) and 5 years (T5) after diagnosis (long-term evaluation).

Secondary

MeasureTime frame
Health-related quality of life, assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) 12 weeks (T2) and 24 weeks (T3) after randomization (short-term evaluation), and 3 years (T4) and 5 Years (T5) after diagnosis (long-term evaluation).

Countries

Sweden

Contacts

Public ContactLena;Claudia Wettergren;Lampic

;

lena.wettergren@ki.se;claudia.lampic@ki.se+46 (0)8 524 83650;+46 (0)8 524 88661

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 3, 2026